JNJ-7777120
JNJ-7777120
JNJ-7777120 (pronunciation: J-N-J Seven Seven Seven Seven One Two Zero) is a potent and selective H4 receptor antagonist. It is a drug that has been studied for its potential therapeutic applications in the treatment of allergic and inflammatory conditions, including asthma and atopic dermatitis.
Etymology
The name "JNJ-7777120" is a compound identifier used in pharmaceutical research. The prefix "JNJ" is an abbreviation for Johnson & Johnson, the multinational corporation that developed the drug. The number "7777120" is a unique identifier assigned to the compound during the drug discovery process.
Pharmacology
JNJ-7777120 is a H4 receptor antagonist, meaning it blocks the action of histamine at the H4 receptor. Histamine is a chemical that triggers allergy symptoms. By blocking the H4 receptor, JNJ-7777120 can potentially reduce these symptoms.
Clinical Trials
JNJ-7777120 has undergone preclinical and early-phase clinical trials for the treatment of allergic and inflammatory conditions. However, as of now, it has not been approved for use in any country.
Related Terms
- Histamine
- Histamine H4 receptor
- Antagonist
- Allergy
- Inflammation
- Asthma
- Atopic dermatitis
- Johnson & Johnson
External links
- Medical encyclopedia article on JNJ-7777120
- Wikipedia's article - JNJ-7777120
This MedicineGPT article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski